Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients
MEDICAL PRINCIPLES AND PRACTICE, cilt.13, sa.6, ss.340-345, 2004 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 6
- Basım Tarihi: 2004
- Doi Numarası: 10.1159/000080471
- Dergi Adı: MEDICAL PRINCIPLES AND PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.340-345
- Anahtar Kelimeler: nasal desmopressin, hemodialysis patients, hemostasis, VONWILLEBRAND-FACTOR, UREMIA, MANAGEMENT, PLATELETS, DIALYSIS, BINDING, DEFECT
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Objective: To evaluate the effect of desmopressin ( DDAVP) on hemostatic parameters during dialysis and in the interval between dialysis sessions. Subjects and Methods: Fifteen patients dialyzed twice weekly at least for 1 year and 15 healthy volunteers serving as a control group were enrolled in the study. Bleeding time, platelet count, prothrombin time, activated partial thromboplastin time, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1), euglobulin clot lysis time, protein C, protein S, fibrinogen, D-dimer, factor V, VII, VIII, IX, X and von Willebrand factor (VWF) values were studied at the beginning, at 2 and 4 h of dialysis with and without administration of DDAVP at a dose level of 2 mug/kg intranasally. Results: After dialysis, bleeding time shortened, PAI-1 and fibrinogen levels were lower, while VWF and D-dimer levels were higher. After DDAVP administration, bleeding time, PAI-1 levels were significantly lower (p < 0.01), while tPA, factor VIII and VWF levels increased significantly (p < 0.001). Conclusion: The findings indicate that DDAVP can be used for patients on dialysis with serious bleeding. Copyright (C) 2004 S. Karger AG, Basel.